Skip to content

EVMN: 3 Funds Holding, Catalyst in 17d | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Evommune, Inc. (EVMN)

Evommune, Inc.

EVMN

Held by 3 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

3 funds opened new positions. Next phase2 readout (EVO756): May 2026. Short interest: 13.4% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

BiotechnologyCEO: Luis C. PenaIPO: 2025Website ↗

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

6.5/10

3 funds opened new positions●●

No recent insider activity●●

Phase2 readout in 17 days●●

Held by 3 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

3 specialist funds hold EVMN with a Phase 2 in 17 days for EVO756 (Chronic Spontaneous Urticaria)

+1 more upcoming catalyst

RTW Investments RA Capital Management Eventide Asset Management

Fund Holdings

3 fund convergence

RTW InvestmentsNew

RA Capital ManagementNew

Eventide Asset ManagementNew

Position Trend

Feb 13, 2026

$16.5M

1 fund

Feb 17, 2026

$81.2M

2 funds

+393% total institutional value over 2 quarters

Short Interest

Float data divergenceHigh short interest

Short Shares

3.25M

Change

-1.8%

Days to Cover

11.8

% of Float

13.4%

Settlement

Apr 30, 2026

Short interest over 6 periods

Catalysts

Phase 2Q2 2026EVO756Chronic Spontaneous UrticariaNCT06873516

Phase 2Q3 2026EVO756Atoptic DermatitisNCT07150845

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13D/ARA Capital Management9.7%Feb 17, 2026

SC 13DRA Capital Management11.0%Nov 17, 2025

Position Details

RTW InvestmentsNEWFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

2 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

BLTE1 fund CLYM1 fund EWTX1 fund TSHA1 fund WAY1 fund WGSWW1 fund WVE1 fund OVID1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: